A Minnesota state representative is seeking to revamp a decades-old pricing law that retail pharmaceutical giants Wal-Mart Stores Inc. and Target Corp. claim prevents them from offering certain generics drugs at $4 in the state.
A judge ruled Friday that a patent dispute between Enzo Biochem Inc. and Applera Corp. will continue with Hunton & Williams LLP representing Enzo, despite General Electric Co.’s attempt to disqualify the firm that is representing its subsidiary in similar litigation against Enzo.
Medical testing company PreMD Inc. has entered into a licensing agreement with an inventor, thus resolving a long-running dispute over patents related to tests for detecting breast, lung and colorectal cancer.
After a bankruptcy judge struck down the orthodontics services company’s Chapter 11 plan Thursday, OCA Inc. has put forth a new plan without the contentious equity deal between a senior lender and some of its shareholders.
The U.S. unit of French drug firm Sanofi-Aventis has become the latest target in a series of lawsuits brought by employees accusing pharmaceutical giants of violating state and federal overtime laws.
A home health care worker will get a second chance to plead her case over minimum wage and overtime pay before the U.S. Supreme Court, the court said on Friday.
The California Institute of Technology has slapped Intuitive Surgical Inc. with a lawsuit, accusing the medical equipment manufacturer of infringing a slew of patents related to a robot-assisted microsurgery system.
In yet another setback for Ariad Pharmaceuticals Inc., a federal appeals court has rejected the drug maker’s request to hear an early appeal of a pretrial ruling in the patent infringement suit filed by rival Amgen Inc.
Drug maker Abbott Laboratories Inc. has been dealt a blow in a patent dispute after a French court ruled a Canadian rival could stop the company from selling a medical device it recently bought from Guidant Corp.
An appeals court has upheld a lower court’s decision to grant a preliminary injunction barring Andrx Corp. from bringing to market a generic version of Abbott Laboratories’ antibiotic Biaxin XL.
Six women who were drugged and sexually assaulted by a former Rite Aid Corp. manager have sued the pharmacy chain for $18 million, accusing it of negligence and inadequate supervision of its employees and prescription drugs.
In a blow to Abbott Laboratories, a federal judge has upheld a jury’s decision to award Belgian biotechnology company Innogenetics NV $7 million in damages in the duo’s long-standing battle over a hepatitis C virus genotyping patent.
Eli Lilly & Co. has reached settlements in about 18,000 claims that the company didn’t properly disclose that patients taking Zyprexa, the company’s schizophrenia drug, were at risk to develop diabetes and other disorders, the company said Thursday.
Swiss pharmaceutical giant Novartis International AG has filed another patent suit against Par Pharmaceuticals, seeking to protect the market for billion-dollar hypertension treatment Lotrel.
The number of new medicines to receive a green light from U.S. regulators reached nearly an eight-year low in 2006, while the number of medicines recommended for sale in 2006 and 2005 fell from the annual average of 26 drugs recorded in the previous six years.
Duane Morris LLP wants a new trial against healthcare bigwig McKesson Corp., because, it claims, there is no longer a conflict between its representation of McKesson subsidiaries in a bankruptcy case and its role in a competition suit against the company.
The Federal Trade Commission reached settlements Thursday with a slew of companies, including Bayer AG and TrimSpa maker Goen Technologies Inc., accused of making false claims about their popular weight-loss products.
Mintz Levin has snared two new partners from a Chicago-based rival in an expansion of its New York health law office.
Patent law firm Fulwider Patton Lee & Utecht LLP has settled with ICU Medical Inc. three years after the health care company sued the firm for allegedly breaching its attorney-client obligations.
United Healthcare Corp. will have to add federal racketeering and antitrust charges to its list of legal woes now that a judge has allowed class action plaintiffs to tack the additional charges onto an ongoing suit.